---
schema_version: "secwatch.filing_event.v1"
accession: "0002023658-25-000034"
form_type: "8-K"
ticker: "BCAX"
cik: "0002023658"
company_name: "Bicara Therapeutics Inc."
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T19:03:35.855119+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Bicara Therapeutics Q1 net loss $36.8M; cash $462M; ASCO data update planned

## Summary
- Cash and cash equivalents of $462.1M as of March 31, 2025, expected to fund operations into H1 2029.
- Net loss of $36.8M in Q1 2025, versus $12.5M in Q1 2024; R&D expenses rose to $34.3M.
- Updated Phase 1/1b data for ficerafusp alfa in 1L R/M HNSCC to be presented at ASCO 2025 (June 1).
- cSCC monotherapy expansion cohort showed ORR of 30.4% and median PFS of 7.0 months at AACR.
- Pivotal Phase 2/3 FORTIFI-HN01 trial enrolling; additional expansion cohorts ongoing or planned.

## SEC filing metadata
- accession: 0002023658-25-000034
- form_type: 8-K
- ticker: BCAX
- cik: 0002023658
- company_name: Bicara Therapeutics Inc.
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2023658/000202365825000034/0002023658-25-000034-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2023658/000202365825000034/bcax-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0002023658-25-000034
- JSON: https://secwatch.observer/filing/0002023658-25-000034.json
- Plain text: https://secwatch.observer/filing/0002023658-25-000034.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.